{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:15:40Z","timestamp":1789179340730,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40259-019-00344-7","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T08:08:00Z","timestamp":1552032480000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Vestronidase Alfa: A Review in Mucopolysaccharidosis VII"],"prefix":"10.1007","volume":"33","author":[{"given":"Emma H.","family":"McCafferty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"issue":"4","key":"344_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/humu.20828","volume":"30","author":"S Tomatsu","year":"2009","unstructured":"Tomatsu S, Monta\u00f1o AM, Dung VC, et al. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome). Hum Mutat. 2009;30(4):511\u20139.","journal-title":"Hum Mutat."},{"issue":"2","key":"344_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","volume":"82","author":"WS Sly","year":"1973","unstructured":"Sly WS, Quinton BA, McAlister WH, et al. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82(2):249\u201357.","journal-title":"J Pediatr."},{"issue":"2","key":"344_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0888-7543(90)90552-6","volume":"7","author":"RD Miller","year":"1990","unstructured":"Miller RD, Hoffmann JW, Powell PP, et al. Cloning and characterization of the human beta-glucuronidase gene. Genomics. 1990;7(2):280\u20133.","journal-title":"Genomics."},{"issue":"5","key":"344_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/rej.2013.1407","volume":"16","author":"H Naz","year":"2013","unstructured":"Naz H, Islam A, Waheed A, et al. Human beta-glucuronidase: structure, function, and application in enzyme replacement therapy. Rejuvenation Res. 2013;16(5):352\u201363.","journal-title":"Rejuvenation Res."},{"key":"344_CR5","unstructured":"Orphanet. Mucopolysaccharidosis type 7. 2019. \n                    http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=584\n                    \n                  . Accessed 31 Jan 2019."},{"key":"344_CR6","unstructured":"National Institutes of Health. Mucopolysaccharidosis type VII. 2018. \n                    https:\/\/ghr.nlm.nih.gov\/condition\/mucopolysaccharidosis-type-vii#\n                    \n                  . Accessed 30 Nov 2018."},{"issue":"6","key":"344_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","volume":"53","author":"AM Montano","year":"2016","unstructured":"Montano AM, Lock-Hock N, Steiner RD, et al. Clinical course of Sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53(6):403\u201318.","journal-title":"J Med Genet."},{"key":"344_CR8","unstructured":"Ultragenyx Pharmaceutical Inc. Mepsevii\u2122 (vestronidase alfa-vjbk): US prescribing information. 2017. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 21 Nov 2018."},{"key":"344_CR9","unstructured":"European Medicines Agency. Vestronidase alfa (Mepsevii): summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 2018."},{"key":"344_CR10","volume-title":"Mepsevii\u2122: Brazilian prescribing information","author":"UNO Healthcare Com\u00e9rcio de Medicamentos Ltda","year":"2018","unstructured":"UNO Healthcare Com\u00e9rcio de Medicamentos Ltda. Mepsevii\u2122: Brazilian prescribing information. S\u00e3o Paulo: UNO Healthcare Com\u00e9rcio de Medicamentos Ltda; 2018."},{"issue":"3","key":"344_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138.","journal-title":"N Engl J Med."},{"issue":"5","key":"344_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-l-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138.","journal-title":"J Pediatr."},{"issue":"8","key":"344_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465\u201373.","journal-title":"Genet Med."},{"issue":"4","key":"344_CR14","doi-asserted-by":"publisher","first-page":"533.e6","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(4):533.e6\u2013539.e6.","journal-title":"J Pediatr."},{"issue":"6","key":"344_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37(6):979\u201390.","journal-title":"J Inherit Metab Dis."},{"issue":"2","key":"344_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","volume":"114","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, et al. Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab. 2015;114(2):178\u201385.","journal-title":"Mol Genet Metab."},{"issue":"7","key":"344_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1172\/JCI1773","volume":"101","author":"LH O\u2019Connor","year":"1998","unstructured":"O\u2019Connor LH, Erway LC, Vogler CA, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Invest. 1998;101(7):1394\u2013400.","journal-title":"J Clin Invest."},{"key":"344_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","volume":"39","author":"C Vogler","year":"1996","unstructured":"Vogler C, Sands MS, Levy B, et al. Enzyme replacement with recombinant \u03b2-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res. 1996;39:1050\u20134.","journal-title":"Pediatr Res."},{"issue":"6","key":"344_CR19","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1172\/JCI117237","volume":"93","author":"MS Sands","year":"1994","unstructured":"Sands MS, Vogler C, Kyle JW, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest. 1994;93(6):2324\u201331.","journal-title":"J Clin Invest."},{"key":"344_CR20","unstructured":"US Food and Drug Administration. Vestronidase alfa (Mepsevii\u2122): clinical pharmacology and biopharmaceuticals review. 2017. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 21 Nov 2018."},{"key":"344_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0721-y","author":"Y Qi","year":"2018","unstructured":"Qi Y, McKeever K, Taylor J, et al. Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials. Clin Pharmacokinet. 2018. \n                    https:\/\/doi.org\/10.1007\/s40262-018-0721-y\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"344_CR22","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01856218. 2018. \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . Accessed 27 Nov 2018."},{"key":"344_CR23","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02418455. 2018. \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . Accessed 27 Nov 2018."},{"issue":"4","key":"344_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","volume":"123","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Whitley CB, Wang RY, et al. A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488\u201394.","journal-title":"Mol Genet Metab."},{"key":"344_CR25","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02432144. 2018. \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . Accessed 27 Nov 2018."},{"key":"344_CR26","unstructured":"European Medicines Agency. Vestronidase alfa (Mepsevii): assessment report. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 26 Nov 2018."},{"key":"344_CR27","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02230566. 2018. \n                    http:\/\/clinicaltrials.gov\/\n                    \n                  . Accessed 27 Nov 2018."},{"key":"344_CR28","first-page":"268","volume":"5","author":"C Haller","year":"2017","unstructured":"Haller C, Song W, Cimms T, et al. Individual heat map assessments demonstrate ERT treatment response in highly heterogeneous MPS VII study population [abstract no. 595 plus poster]. J Inborn Errors Metab Screen. 2017;5:268\u20139.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"Suppl. 1","key":"344_CR29","first-page":"S188","volume":"41","author":"EM Martins","year":"2018","unstructured":"Martins EM, Wang RYW, Francisco Da Silva Franco JF, et al. Sustained efficacy and safety of long-term vestronidase alfa (rhGUS) enzyme replacement therapy in patients with MPS VII [abstract no. P-372 plus poster]. J Inherit Metab Dis. 2018;41(Suppl. 1):S188.","journal-title":"J Inherit Metab Dis."},{"issue":"Suppl. 1","key":"344_CR30","first-page":"S48","volume":"39","author":"M Coker","year":"2016","unstructured":"Coker M, Gonzales-Meneses Lopez A, Song W, et al. Long-term outcomes with rhGUS in a phase I\/II clinical trial in MPS VII [abstract no. O-044]. J Inherit Metab Dis. 2016;39(Suppl. 1):S48\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl. 1","key":"344_CR31","first-page":"S187","volume":"41","author":"AGL Gonzalez-Meneses Lopez","year":"2018","unstructured":"Gonzalez-Meneses Lopez AGL, Beuno MB, Lau HL, et al. Vestronidase alfa stabilizes or improves disease manifestations in subjects with MPS VII [abstract no. P-371]. J Inherit Metab Dis. 2018;41(Suppl. 1):S187\u20138.","journal-title":"J Inherit Metab Dis."},{"key":"344_CR32","unstructured":"Ali QA, Lopez AG-M, Viskochil DV, et al. The enzyme replacement therapy vestronidase alfa stabilizes or improves disease manifestations in subjects with MPS VII <5-years old [abstract]. In: Canadian Symposium on Lysosomal Diseases. 2018."},{"issue":"2","key":"344_CR33","first-page":"S71","volume":"117","author":"HA Lau","year":"2016","unstructured":"Lau HA, Parmar S, Kazachkov M, et al. Enzyme replacement therapy with investigational rhGUS in an infant with non-immune hydrops fetalis and mucopolysaccharidosis type VII [abstract no. 173 plus poster]. Mol Genet Metab. 2016;117(2):S71.","journal-title":"Mol Genet Metab."},{"key":"344_CR34","unstructured":"US Food and Drug Administration. UX003\/rhGUS: clinical review. 2017. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 21 Nov 2018."},{"issue":"2","key":"344_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","volume":"114","author":"JE Fox","year":"2015","unstructured":"Fox JE, Volpe L, Bullaro J, et al. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015;114(2):203\u20138.","journal-title":"Mol Genet Metab."},{"key":"344_CR36","doi-asserted-by":"crossref","unstructured":"Marsden D, Hostutler R, Cimms T, et al. The MPS VII Disease Monitoring Program is a novel longitudinal, cohort program with a rigor beyond a traditional registry [abstract no. 229 plus poster]. In: WORLD Symposium. 2019.","DOI":"10.1016\/j.ymgme.2018.12.245"},{"key":"344_CR37","unstructured":"Society for Mucopolysaccharide Diseases. Guide to understanding mucopolysaccharidosis VII (MPS VII). 2015. \n                    http:\/\/www.mpssociety.org.uk\/\n                    \n                  . Accessed 4 Dec 2018."},{"key":"344_CR38","unstructured":"US Food and Drug Administration. Vestronidase alfa (Mepsevii\u2122): risk assessment and risk mitigation review. 2017. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 21 Nov 2018."},{"issue":"7","key":"344_CR39","doi-asserted-by":"publisher","first-page":"e13278","DOI":"10.1111\/petr.13278","volume":"22","author":"L Sisinni","year":"2018","unstructured":"Sisinni L, Pineda M, Coll MJ, et al. Haematopoietic stem cell transplantation for mucopolysaccharidosis type VII: a case report. Pediatr Transplant. 2018;22(7):e13278.","journal-title":"Pediatr Transplant."},{"key":"344_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","volume":"21","author":"Y Yamada","year":"1998","unstructured":"Yamada Y, Kato K, Sukegawa K, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1998;21:629\u201334.","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"344_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/21678707.2018.1529564","volume":"6","author":"VM Ginocchio","year":"2018","unstructured":"Ginocchio VM, Brunetti-Pierri N. Recent progress in gene therapies for mucopolysaccharidoses. Expert Opin Orphan Drugs. 2018;6(10):611\u201323.","journal-title":"Expert Opin Orphan Drugs."},{"key":"344_CR42","unstructured":"Ultracare\u2122. Ultracare: assistance in gaining access to Mepsevii (vestronidase alfa-vjbk). 2019. \n                    http:\/\/ultracaresupport.com\/mepsevii\/\n                    \n                  . Accessed 31 Jan 2019."},{"key":"344_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.07.001","author":"M Stapleton","year":"2018","unstructured":"Stapleton M, Hoshina H, Sawamoto K, et al. Critical review of current MPS guidelines and management. Mol Genet Metab. 2018. \n                    https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.001\n                    \n                  .","journal-title":"Mol Genet Metab."},{"issue":"2","key":"344_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111(2):63\u201372.","journal-title":"Mol Genet Metab."}],"updated-by":[{"DOI":"10.1007\/s40259-019-00353-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-019-00344-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T11:14:50Z","timestamp":1592306090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-019-00344-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00344-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-019-00353-6","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"8 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Vestronidase Alfa: A Review in Mucopolysaccharidosis VII, written by Emma H. McCafferty and Lesley J. Scott, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma McCafferty and Lesley Scott are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}